Reports Q1 2023 results
As expected, we see some fluctuation in Idefirix sales with Q1 2023 posting SEK 14.3m compared to SEK 24.2m in Q1 2022. We reiterate that this is not of concern as the figure reflects a small number of patients, and we believe that Hansa will increase sales for FY 2023 (we est. SEK 142m, consensusHansa Medical is a biopharmaceutical company focusing on novel immunomodulatory enzymes. The research project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Additional projects focus on development of new antibody modulating enzymes, as well as HBP, a diagnostic biomarker for prediction of severe sepsis at emergency departments that is already introduced on the market. Co.'s business consists of research and development for production of pharmaceuticals.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.